<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526499</url>
  </required_header>
  <id_info>
    <org_study_id>TCvsT</org_study_id>
    <nct_id>NCT01526499</nct_id>
  </id_info>
  <brief_title>Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of metronomic cyclophosphamide in addition
      to docetaxel in first line therapy in metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metronomic chemotherapy has been considered as an effective strategy for metastatic breast
      cancer. This trial is designed to evaluate the role of metronomic cyclophosphamide in
      addition to docetaxel in first line therapy in metastatic breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker serum VEGF level</measure>
    <time_frame>6 weeks</time_frame>
    <description>Relationship of serum VEGF level and efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker immuno-marker</measure>
    <time_frame>6 weeks</time_frame>
    <description>Relationship of immuno-marker(CD3,CD4,CD8 ect) and efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Overall Response Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Overall Survival</measure>
    <time_frame>6 weeks</time_frame>
    <description>Overall Survival, OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety（NCI CTCAE v4.0）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genetic polymorphisms</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate the relationship of genetic polymorphisms and efficacy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus Cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel and Cyclophosphamide (TC)</intervention_name>
    <description>Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days</description>
    <arm_group_label>TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel (T)</intervention_name>
    <description>Docetaxel 75mg/m2 IVGTT D1;every 21days</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with age between 18 and 70 years old

          2. ECOG performance between 0-1

          3. Life expectancy more than 3 months

          4. Histological proven unresectable recurrent or advanced breast cancer

          5. No previous chemotherapy for metastatic breast cancer;suitable for monotherapy
             (Neoadjuvant or adjuvant docetaxel should be completed at least one year).

          6. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST1.1)

          7. No anticancer therapy within 4 weeks

          8. Adequate hematologic, hepatic, and renal function,No serious medical history of heart,
             lung, liver and kidney

          9. Provision of written informed consent prior to any study specific procedures

        Exclusion Criteria:

          1. Pregnant or lactating women (female patients of child-bearing potential must have a
             negative serum pregnancy test within 14 days of first day of drug dosing, or, if
             positive, a pregnancy ruled out by ultrasound)

          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection
             during the course of the study

          3. Treatment with an investigational product within 4 weeks before the first treatment

          4. Symptomatic central nervous system metastases

          5. Other active malignancies (including other hematologic malignancies) or other
             malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial
             neoplasia.

          6. Patient having a history of clinically significant cardiovascular, hepatic,
             respiratory or renal diseases, clinically significant hematological and endocrinal
             abnormalities, clinically significant neurological or psychiatric conditions

          7. Uncontrolled serious infection

          8. Patients with bad compliance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhonghua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leiping Wang, MD</last_name>
    <phone>+862164175590</phone>
    <email>leipingwang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leiping Wang, MD</last_name>
      <phone>+862164175590</phone>
      <phone_ext>8908</phone_ext>
      <email>leipingwang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>February 5, 2012</last_update_submitted>
  <last_update_submitted_qc>February 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>yanfei Liu</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Metronomic cyclophosphamide</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>first line</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

